BACKGROUND: A total of 8.3 million HIV-positive people live in the Asia-Pacific region. The burden of HIV-associated neurocognitive impairment and symptomatic sensory neuropathy in this region is unknown. METHODS: Between July 2005 and March 2006, we undertook a cross-sectional study at 10 sentinel sites within eight Asia-Pacific countries to determine the prevalence of moderate to severe HIV-related neurocognitive impairment and symptomatic sensory neuropathy. We clinically assessed and administered sensitive neuropsychological and peripheral neuropathy screening tools to 658 patients infected with HIV. Univariate and logistic regression analyses were applied to the data. RESULTS: The results showed that 76 patients (11.7%) (95% CI 9.3-14.2) were significantly neurocognitively impaired, 235 patients (36.4%) (95% CI 32.7-40.2) were depressed, and 126 patients (19.7%) (95% CI 16.6-22.8) had either definite or probable symptomatic sensory neuropathy; 63% of this last group had exposure to stavudine, didanosine, or zalcitabine. Several potential confounders including depression (OR 1.49, 95% CI 0.88-2.51, p = 0.11) and prior CNS AIDS illness (OR 1.28, 95% CI 0.50-2.89, p = 0.54) were not significantly associated with neurocognitive impairment. CONCLUSIONS: A total of 12% of patients had moderate to severe HIV-related neurocognitive impairment, 20% of patients had symptomatic sensory neuropathy, and 36% of patients had evidence of depression. This study provides a broad regional estimate of the burden of HIV-related neurologic disease and depression in the Asia-Pacific region.
BACKGROUND: A total of 8.3 million HIV-positive people live in the Asia-Pacific region. The burden of HIV-associated neurocognitive impairment and symptomatic sensory neuropathy in this region is unknown. METHODS: Between July 2005 and March 2006, we undertook a cross-sectional study at 10 sentinel sites within eight Asia-Pacific countries to determine the prevalence of moderate to severe HIV-related neurocognitive impairment and symptomatic sensory neuropathy. We clinically assessed and administered sensitive neuropsychological and peripheral neuropathy screening tools to 658 patients infected with HIV. Univariate and logistic regression analyses were applied to the data. RESULTS: The results showed that 76 patients (11.7%) (95% CI 9.3-14.2) were significantly neurocognitively impaired, 235 patients (36.4%) (95% CI 32.7-40.2) were depressed, and 126 patients (19.7%) (95% CI 16.6-22.8) had either definite or probable symptomatic sensory neuropathy; 63% of this last group had exposure to stavudine, didanosine, or zalcitabine. Several potential confounders including depression (OR 1.49, 95% CI 0.88-2.51, p = 0.11) and prior CNS AIDS illness (OR 1.28, 95% CI 0.50-2.89, p = 0.54) were not significantly associated with neurocognitive impairment. CONCLUSIONS: A total of 12% of patients had moderate to severe HIV-related neurocognitive impairment, 20% of patients had symptomatic sensory neuropathy, and 36% of patients had evidence of depression. This study provides a broad regional estimate of the burden of HIV-related neurologic disease and depression in the Asia-Pacific region.
Authors: Alejandro Arenas-Pinto; Jennifer Thompson; Godfrey Musoro; Hellen Musana; Abbas Lugemwa; Andrew Kambugu; Aggrey Mweemba; Dickens Atwongyeire; Margaret J Thomason; A Sarah Walker; Nicholas I Paton Journal: J Neurovirol Date: 2015-08-25 Impact factor: 2.643
Authors: Lucette A Cysique; Scott L Letendre; Christopher Ake; Hua Jin; Donald R Franklin; Saurabh Gupta; Chuan Shi; Xin Yu; Zunyou Wu; Ian S Abramson; Igor Grant; Robert K Heaton Journal: AIDS Date: 2010-04-24 Impact factor: 4.177
Authors: Edwina J Wright; Birgit Grund; Kevin R Robertson; Lucette Cysique; Bruce J Brew; Gary L Collins; Mollie Poehlman-Roediger; Michael J Vjecha; Augusto César Penalva de Oliveira; Barbara Standridge; Cate Carey; Anchalee Avihingsanon; Eric Florence; Jens D Lundgren; Alejandro Arenas-Pinto; Nicolas J Mueller; Alan Winston; Moses S Nsubuga; Luxshimi Lal; Richard W Price Journal: AIDS Date: 2018-05-15 Impact factor: 4.177
Authors: Farrah J Mateen; Russell T Shinohara; Marco Carone; Eric N Miller; Justin C McArthur; Lisa P Jacobson; Ned Sacktor Journal: Neurology Date: 2012-10-17 Impact factor: 9.910
Authors: Jeymohan Joseph; Cristian L Achim; Michael J Boivin; Bruce J Brew; David B Clifford; Deborah A Colosi; Ronald J Ellis; Robert K Heaton; Amadou Gallo-Diop; Igor Grant; Georgette D Kanmogne; Mahendra Kumar; Scott Letendre; Thomas D Marcotte; Avindra Nath; Carlos A Pardo; Robert H Paul; Lynn Pulliam; Kevin Robertson; Walter Royal; Ned Sacktor; Pasiri Sithinamsuwan; Davey M Smith; Victor Valcour; Brian Wigdahl; Charles Wood Journal: J Neurovirol Date: 2013-01-26 Impact factor: 2.643